Grant ID RP240104
Awarded On February 21, 2024
Title Characterization and optimization of novel allosteric KRAS inhibitors
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Alemayehu Gorfe
Cancer Sites Colorectal, Lung and Bronchus, Pancreas
Contracted Amount $1,050,000
Lay Summary

A fifth of all human cancers, including nearly all pancreatic and about half of colorectal cancers, are caused by mutations in a particular enzyme called KRAS. After decades of neglect as an intractable therapeutic target, KRAS is now arguably the most sought-after drug target attracting intense attention from pharmaceutical and academic laboratories alike. Among the major breakthroughs in recent years is the approval by the Food and Drug Administration of Lumakras and Krazati for the treatment of non-small cell lung cancer. These drugs work by irreversibly attaching to a particular KRAS mutant, G12C. Therefore, their use is limited to patients carrying this specific KRAS mutation. Other typ...

Read More